Corvus Pharmaceuticals COVID-19 Abstract Selected for “Hot Topic” Oral Session at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
The abstract, which is also being presented as a poster at the SITC meeting, will be included in the “Hot Topic Symposium: COVID-19 and Cancer” session, which is taking place on
R&D Symposium Conference Call, Webcast and Presentation Slides
Corvus will host an R&D Symposium on
Tullia C. Bruno, PhD, Assistant Professor, Department of Immunologyat UPMC Hillman Cancer Center. Dr. Brunowill provide an overview of B cell biology and antibodies. Gerard J. Criner, M.D., Chair and Professor, lead investigator of the CPI-006 COVID-19 Phase 1 study, and Chair and Professor, Thoracic Medicine and Surgery at the Lewis Katz School of Medicineat Temple University. Dr. Crinerwill provide an overview of current COVID-19 therapies and results from the CPI-006 COVID-19 Phase 1 study.
Members of the Corvus team will provide an overview of the preclinical biology and data on CPI-006, plans for the CPI-006 pivotal study for patients with COVID-19, and a general pipeline update covering the Company’s cancer programs. The speakers will be available for questions and answers during the program.
The R&D Symposium conference call can be accessed by dialing 1-877-423-9813 (toll-free domestic) or 1-201-689-8573 (international) and using the conference ID 13712583. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.
About Corvus Pharmaceuticals
CPI-006 is an investigational, potent humanized monoclonal antibody that is designed to react with a specific site on CD73. In preclinical studies, it has demonstrated immunomodulatory activity resulting in activation of lymphocytes, induction of antibody production from B cells and effects on lymphocyte trafficking. While there are other anti-CD73 antibodies in development for treatment of cancer, such antibodies have been reported to react with a different region of CD73 and are designed to block production of adenosine, which is not involved in the immunomodulatory processes seen with CPI-006. CPI-006 is currently being evaluated in an ongoing Phase 1 study in patients with COVID-19 and has demonstrated enhanced antibody responses to the SARS-CoV-2 virus.
Chief Financial Officer
Source: Corvus Pharmaceuticals, Inc.